Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive ...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanofi and Regeneron ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type-2 inflammation. In addition to the ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

SNY Sanofi Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis Approval based on Phase 3 data showing ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), combined with a standard-of-care regimen to treat adults with newly ...

The FDA approved Aubagio ... the European Medicines Agency (EMA), which has been accepted for regulatory review. We currently have a Neutral recommendation on Sanofi. The stock carries a Zacks ...